Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI
  • Top
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Erratum Free access | 10.1172/JCI74035

Predicting time to ovarian carcinoma recurrence using protein markers

Ji-Yeon Yang, Kosuke Yoshihara, Kenichi Tanaka, Masayuki Hatae, Hideaki Masuzaki, Hiroaki Itamochi, The Cancer Genome Atlas (TCGA) Research Network, Masashi Takano, Kimio Ushijima, Janos L. Tanyi, George Coukos, Yiling Lu, Gordon B. Mills, and Roel G.W. Verhaak

Find articles by Yang, J. in: JCI | PubMed | Google Scholar

Find articles by Yoshihara, K. in: JCI | PubMed | Google Scholar

Find articles by Tanaka, K. in: JCI | PubMed | Google Scholar

Find articles by Hatae, M. in: JCI | PubMed | Google Scholar

Find articles by Masuzaki, H. in: JCI | PubMed | Google Scholar

Find articles by Itamochi, H. in: JCI | PubMed | Google Scholar

Find articles by Takano, M. in: JCI | PubMed | Google Scholar

Find articles by Ushijima, K. in: JCI | PubMed | Google Scholar

Find articles by Tanyi, J. in: JCI | PubMed | Google Scholar

Find articles by Coukos, G. in: JCI | PubMed | Google Scholar

Find articles by Lu, Y. in: JCI | PubMed | Google Scholar

Find articles by Mills, G. in: JCI | PubMed | Google Scholar

Find articles by Verhaak, R. in: JCI | PubMed | Google Scholar

Published December 2, 2013 - More info

Published in Volume 123, Issue 12 on December 2, 2013
J Clin Invest. 2013;123(12):5410–5410. https://doi.org/10.1172/JCI74035.
© 2013 The American Society for Clinical Investigation
Published December 2, 2013 - Version history
View PDF

Related article:

Predicting time to ovarian carcinoma recurrence using protein markers
Ji-Yeon Yang, … , Gordon B. Mills, Roel G.W. Verhaak
Ji-Yeon Yang, … , Gordon B. Mills, Roel G.W. Verhaak
Research Article Oncology

Predicting time to ovarian carcinoma recurrence using protein markers

  • Text
  • PDF
Abstract

Patients with ovarian cancer are at high risk of tumor recurrence. Prediction of therapy outcome may provide therapeutic avenues to improve patient outcomes. Using reverse-phase protein arrays, we generated ovarian carcinoma protein expression profiles on 412 cases from TCGA and constructed a PRotein-driven index of OVARian cancer (PROVAR). PROVAR significantly discriminated an independent cohort of 226 high-grade serous ovarian carcinomas into groups of high risk and low risk of tumor recurrence as well as short-term and long-term survivors. Comparison with gene expression–based outcome classification models showed a significantly improved capacity of the protein-based PROVAR to predict tumor progression. Identification of protein markers linked to disease recurrence may yield insights into tumor biology. When combined with features known to be associated with outcome, such as BRCA mutation, PROVAR may provide clinically useful predictions of time to tumor recurrence.

Authors

Ji-Yeon Yang, Kosuke Yoshihara, Kenichi Tanaka, Masayuki Hatae, Hideaki Masuzaki, Hiroaki Itamochi, Masashi Takano, Kimio Ushijima, Janos L. Tanyi, George Coukos, Yiling Lu, Gordon B. Mills, Roel G.W. Verhaak

×

Original citation: J Clin Invest. 2010;123(9):3740–3750. doi:10.1172/JCI68509.

Citation for this erratum: J Clin Invest. 2013;123(12):5410. doi:10.1172/JCI74035.

Some expressions and notations related to Equations 1 and 2 were presented incorrectly. The correct text and equations are below.

The coefficients (β) in Cox’s regression model are estimated by maximizing the partial likelihood function subject to a constraint on the L1-norm of the coefficients. The lasso estimator (β̂) maximizes the objective function given below:

(Equation 1)

Here l(β) is the log partial likelihood in the Cox model; for the exact form of this function, see ref. 41. The tuning parameter, λ in Equation 1, was chosen by 10-fold cross-validation. For the implementation, we used the R package “glmnet” (39).

PROVAR was defined for each of the 222 TCGA samples as the sum of the estimated coefficients multiplied by protein expression levels, as shown below. Here i represents patients (i = 1, ..., 222), j represents proteins with nonzero coefficients (j = 1, ..., m), β̂j is the lasso coefficient of the jth protein marker, and Xij is the expression level of the jth protein for the ith patient.

(Equation 2)

The JCI regrets the error.

Version history
  • Version 1 (December 2, 2013): No description

Article tools

  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Version history
Advertisement
Advertisement
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts